Background: Ventilator-associated pneumonia (VAP) is the most frequent infection with high mortality rates in intensive care units (ICUs) and the prediction of outcome is important in the decision-making process. Objective: To assess the value of the Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) and Clinical Pulmonary Infection Score (CPIS) in the prediction of mortality during VAP episodes in pulmonary patients. Methods: This study was a prospective observational cohort study. Sixty-three patients who were admitted to the ICU and developed VAP were included in the study consecutively. Clinical and laboratory data conforming to the APACHE II and SOFA scores were recorded on admission and APACHE II, SOFA and CPIS scores on the day of the diagnosis of VAP. The outcome measure was the ICU mortality. Logistic regression and receiver operating characteristic (ROC) curve analyses and the area under the curve (AUC) were used to estimate the predictive ability of the scoring systems. Results: Mortality rate was 54%. The mean APACHE II (21 ± 6, 14 ± 5; p = 0.001), SOFA (7 ± 3, 4 ± 2; p = 0.002) and CPIS (8 ± 2, 7 ± 3; p = 0.025) scores determined at the time of VAP diagnosis were significantly higher in nonsurvivors than in survivors. Discrimination was excellent for APACHE II (ROC AUC: 0.81; p = 0.001) and acceptable for SOFA (ROC AUC: 0.71; p = 0.005) scores. Of the three scores only APACHE II >16 was an independent predictor of the mortality (OR: 5; 95% CI: 1.3–18; p = 0.019) in the logistic regression analysis. Conclusion: These results suggest that APACHE II determined at the time of VAP diagnosis may be useful in predicting mortality in the pulmonary ICU patient population who develops VAP.

Keywords:
Ventilator-associated pneumonia, APACHE II, SOFA, CPIS
1.
Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al: The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995;274:639–644.
2.
Gursel G: Determinants of length of mechanical ventilation in patients with COPD during their ICU stay. Respiration 2005;72:61–67.
3.
Heyland DK, Cook DJ, Griffith L, Keenan S, Brun-Buisson C: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 1999;159:1249–1256.
4.
Bonten MJ, Froon AH, Gaillard CA, Greve JW, de Leeuw PW, Drent M, et al: The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:1105–1113.
5.
Knaus WA, Draper EA, Wagner DP: A severity of disease classification system. Crit Care Med 1985;13:1818–1829.
6.
Vincent JL, De Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care unit: results of a multicenter, prospective study. Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Crit Care Med 1998;26:1793–1800.
7.
Pugin J, Auckenthaler R, Mili N, Janssens IP, Lew PD, Suter PM: Diagnosis of ventilator associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic ‘blind’ bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121–1129.
8.
Rutledge R, Fakhry S, Rutherford E, Muakkassa F, Meyer A: Comparison of APACHE II, Trauma Score, and Injury Severity Score as predictors of outcome in critically injured trauma patients. Am J Surg 1993;166:244–247.
9.
Bohnen JM, Mustard RA, Schouten BD: Steroids, APACHE II score, and the outcome of abdominal infection. Arch Surg 1994;129:33–37.
10.
Fan ST, Lai EC, Mok FP, Lo CM, Zheng SS, Wong J: Prediction of the severity of acute pancreatitis. Am J Surg 1993;166:262–268.
11.
Goel A, Pincney RG, Littenberg B: APACHE II predicts long-term survival in COPD patients admitted to a general medical ward. J Gen Intern Med 2003;18:824–830.
12.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–874.
13.
Iregui M, Ward S, Sherma G, Fraser VJ, Kollef MH: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262–268.
14.
Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.
15.
Zhu BP, Lemeshow S, Hosmer DW, Klar J, Avrunin J, Teres D: Factors affecting the performance of the models in the mortality probability model II system and strategies of customization: a simulation study. Crit Care Med 1996;24:57–63.
16.
Cook DJ, Walter SD, Cook RJ, et al: Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433–440.
17.
Chastre J, Fagon JY: Ventilator-associated pneumonia. State of the art. Am J Respir Crit Care Med 2002;165:867–903.
18.
Blasi F, Tarsia P, Aliberti S: Strategic targets of essential host-pathogen interactions. Respiration 2005;72:9–25.
19.
Kollef M: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31:S131–S138.
20.
Carson SS, Bach PB: Predicting mortality in patients suffering from prolonged critical illness: an assessment of four severity of illness measures. Chest 2001;120:928–933.
21.
Fiaccadori E, Maggiore U, Lombardi M, Leonardi S, Rotelli C, Borghetti A: Predicting patient outcome from acute renal failure comparing three general severity of illness scoring systems. Kidney Int 2000;58:283–292.
22.
Jacobs S, Zuleika M, Mphansa T: The multiple organ dysfunction score as a descriptor of patient outcome in septic shock compared with two other scoring system. Crit Care Med 1999;27:741–744.
23.
Riberio KC, Kowalsky LP: APACHE II, POSSUM, and ASA scores and the risk of perioperative complications in patients with oral or oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2003;129:739–745.
24.
Leroy O, Meybek A, d’Escrivan T, Devos P, Kipnis F, Gearges H: Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator associated pneumonia. Intensive Care Med 2003;29:2170–2173.
25.
Froon AH, Bonten M, Gaillard CA, Greve JW, Dentener MA, de Leeuw PW, et al: Prediction of clinical severity and outcome of ventilator-associated pneumonia. Comparison of simplified acute physiology score with systemic inflammatory mediators. Am J Respir Crit Care Med 1998;158:1026–1031.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.